Marco Galvez-Nino
Overview
Explore the profile of Marco Galvez-Nino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Evaluation of Multiple Breast Cancer Polygenic Risk Score Panels in Women of Latin American Heritage
Huang X, Lott P, Hu D, Zavala V, Jamal Z, Vidaurre T, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Dec;
34(2):234-245.
PMID: 39625644
Background: A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been...
2.
Arrieta O, Ramos-Ramirez M, Garces-Flores H, Cabrera-Miranda L, Gomez-Garcia A, Soto-Molina H, et al.
Oncologist
. 2024 Oct;
PMID: 39427228
Background: Using immune checkpoint inhibitors (IO) is a promising approach to maximize clinical benefits for patients with non-small cell lung cancer (NSCLC). PD-L1 expression serves as a predictive factor for...
3.
Enrico D, Gomez J, Aguirre D, Tissera N, Tsou F, Pupareli C, et al.
Clin Lung Cancer
. 2024 Oct;
25(8):723-731.e2.
PMID: 39424512
Background: The phase 3 CheckMate-743 trial demonstrated a prolonged overall survival (OS) benefit with nivolumab plus ipilimumab over chemotherapy as first-line treatment in patients with unresectable pleural mesothelioma (PM). However,...
4.
Zanabria D, Galvez-Nino M, Araujo J, Alfaro A, Fajardo W, Saravia L, et al.
Sci Rep
. 2024 Jul;
14(1):15070.
PMID: 38956258
The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration of the possibility that patients from different socioeconomic backgrounds may be exposed to...
5.
Villanueva-Cotrina F, Velarde J, Rodriguez R, Bonilla A, Laura M, Saavedra T, et al.
Pathol Oncol Res
. 2023 Sep;
29:1611236.
PMID: 37746553
The role of the type, stage and status of cancer in the outcome of COVID-19 remains unclear. Moreover, the characteristic pathological changes of severe COVID-19 reveled by laboratory and radiological...
6.
Lara-Mejia L, Cardona A, Mas L, Martin C, Samtani S, Corrales L, et al.
J Thorac Oncol
. 2023 Aug;
19(1):119-129.
PMID: 37572870
Introduction: ALK tyrosine kinase inhibitors have exhibited promising activity against advanced ALK-rearranged NSCLC. However, co-occurring genetic alterations, such as CDKN2A/B or TP53, may negatively affect the efficacy of targeted therapies....
7.
Zavala V, Casavilca-Zambrano S, Navarro-Vasquez J, Tamayo L, Castaneda C, Valencia G, et al.
Front Oncol
. 2023 Mar;
13:938042.
PMID: 36925912
Introduction: Breast cancer is a heterogeneous disease, and the distribution of the different subtypes varies by race/ethnic category in the United States and by country. Established breast cancer-associated factors impact...
8.
Heredia D, Mas L, Cardona A, Oyervides V, Guerrero R, Galvez-Nino M, et al.
Lung Cancer
. 2022 Nov;
174:133-140.
PMID: 36379126
Background: Co-occurring genomic alterations identified downstream main oncogenic drivers have become more evident since the introduction of next-generation sequencing (NGS) analyses at diagnosis and progression. Emerging evidence has stated that...
9.
Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru
Galvez-Nino M, Ruiz R, Roque K, Coanqui O, Valdivieso N, Olivera M, et al.
Thorac Cancer
. 2022 Nov;
14(1):61-67.
PMID: 36369763
Background: Despite the advances in the management of advanced non-small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in...
10.
Ruiz R, Galvez-Nino M, Roque K, Montes J, Nunez M, Raez L, et al.
Front Oncol
. 2022 Oct;
12:910117.
PMID: 36263208
Background: Lung cancer in the young is a rare entity of great interest due to the high frequency of targetable mutations. In this study, we explored the genomic landscape of...